



CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

Award ID:
DP150029

Project Title:
Personalized Cellular Immunotherapy against Novel Cancer Targets

Award Mechanism:
New Company Product Development Award

Principal Investigator:
Steffen, Walter

Entity:
Immatics US Inc.

Lay Summary:

Immatics GmbH (Germany) has been successfully developing off-the-shelf cancer immunotherapies for the past decade. Immatics US Inc. (Houston, Texas), a newly created subsidiary of Immatics GmbH, is a first-in-class biopharmaceutical company dedicated to the development of novel personalized cancer immunotherapies including (1) adoptive cellular therapy (ACT) and (2) actively personalized vaccines (APVACs). Both types of immunotherapies activate the patient's immune cells (so-called T cells) either outside or inside the body, respectively. Both types are tailored to characteristics of the individual tumor tissue, thus maximizing chances of successful therapy for the individual patient. T-cell based immunotherapy is emerging as a standard of care for patients suffering from certain skin and blood cancers based in part on work at MD Anderson Cancer Center (MDACC). However, the field lacks suitable and safe targets to translate these initial successes to other cancer types. Immatics will bring to Texas its globally leading antigen discovery platform XPRESIDENT® enabling rapid discovery of new, suitable and safe cancer targets for immunotherapy. A critical mass of leading immunotherapy experts and the unique clinical infrastructure available in Houston will strongly accelerate Immatics US Inc.'s mission to build a sustainable, world-class cancer immunotherapy company in Texas and translate the value of novel cancer targets into better and longer lives for cancer patients.